These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 25355697)

  • 1. Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention.
    Bergstrand M; Nosten F; Lwin KM; Karlsson MO; White NJ; Tarning J
    Sci Transl Med; 2014 Oct; 6(260):260ra147. PubMed ID: 25355697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.
    Lwin KM; Phyo AP; Tarning J; Hanpithakpong W; Ashley EA; Lee SJ; Cheah P; Singhasivanon P; White NJ; Lindegårdh N; Nosten F
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1571-7. PubMed ID: 22252804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling Prevention of Malaria and Selection of Drug Resistance with Different Dosing Schedules of Dihydroartemisinin-Piperaquine Preventive Therapy during Pregnancy in Uganda.
    Wallender E; Zhang N; Conrad M; Kakuru A; Muhindo M; Tumwebaze P; Kajubi R; Mota D; Legac J; Jagannathan P; Havlir D; Kamya M; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine.
    Permala J; Tarning J; Nosten F; White NJ; Karlsson MO; Bergstrand M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.
    Sambol NC; Tappero JW; Arinaitwe E; Parikh S
    PLoS One; 2016; 11(5):e0154623. PubMed ID: 27182702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
    Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
    Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy.
    Chotsiri P; Gutman JR; Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Asih PBS; L'lanziva A; Otieno K; Kariuki S; Ouma P; Were V; Katana A; Price RN; Desai M; Ter Kuile FO; Tarning J
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children.
    Chotsiri P; Zongo I; Milligan P; Compaore YD; Somé AF; Chandramohan D; Hanpithakpong W; Nosten F; Greenwood B; Rosenthal PJ; White NJ; Ouédraogo JB; Tarning J
    Nat Commun; 2019 Jan; 10(1):480. PubMed ID: 30696903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.
    Whalen ME; Kajubi R; Chamankhah N; Huang L; Orukan F; Wallender E; Kamya MR; Dorsey G; Jagannathan P; Rosenthal PJ; Mwebaza N; Aweeka FT
    Clin Pharmacol Ther; 2019 Dec; 106(6):1310-1318. PubMed ID: 31173649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers.
    Chotsiri P; Wattanakul T; Hoglund RM; Hanboonkunupakarn B; Pukrittayakamee S; Blessborn D; Jittamala P; White NJ; Day NPJ; Tarning J
    Br J Clin Pharmacol; 2017 Dec; 83(12):2752-2766. PubMed ID: 28695570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malaria Chemoprevention in the Postdischarge Management of Severe Anemia.
    Kwambai TK; Dhabangi A; Idro R; Opoka R; Watson V; Kariuki S; Kuya NA; Onyango ED; Otieno K; Samuels AM; Desai MR; Boele van Hensbroek M; Wang D; John CC; Robberstad B; Phiri KS; Ter Kuile FO
    N Engl J Med; 2020 Dec; 383(23):2242-2254. PubMed ID: 33264546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants.
    Creek DJ; Bigira V; McCormack S; Arinaitwe E; Wanzira H; Kakuru A; Tappero JW; Sandison TG; Lindegardh N; Nosten F; Aweeka FT; Parikh S
    J Infect Dis; 2013 Jun; 207(11):1646-54. PubMed ID: 23447696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
    Hughes E; Imperial M; Wallender E; Kajubi R; Huang L; Jagannathan P; Zhang N; Kakuru A; Natureeba P; Mwima MW; Muhindo M; Mwebaza N; Clark TD; Opira B; Nakalembe M; Havlir D; Kamya M; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria.
    Tarning J; Lindegardh N; Lwin KM; Annerberg A; Kiricharoen L; Ashley E; White NJ; Nosten F; Day NP
    Antimicrob Agents Chemother; 2014; 58(4):2052-8. PubMed ID: 24449770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria.
    Darpo B; Ferber G; Siegl P; Laurijssens B; Macintyre F; Toovey S; Duparc S
    Br J Clin Pharmacol; 2015 Oct; 80(4):706-15. PubMed ID: 25966781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz-Based Antiretroviral Therapy but Not Pregnancy Increased Unbound Piperaquine Exposure in Women during Malaria Chemoprevention.
    Hong H; Aslam-Mir U; Kajubi R; Wallender E; Mwebaza N; Dorsey G; Rosenthal PJ; Aweeka FT; Huang L
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0142722. PubMed ID: 36916944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperaquine: a resurgent antimalarial drug.
    Davis TM; Hung TY; Sim IK; Karunajeewa HA; Ilett KF
    Drugs; 2005; 65(1):75-87. PubMed ID: 15610051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso.
    Zongo I; Dorsey G; Rouamba N; Dokomajilar C; Séré Y; Rosenthal PJ; Ouédraogo JB
    Clin Infect Dis; 2007 Dec; 45(11):1453-61. PubMed ID: 17990228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
    Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD
    Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The application of physiologically based pharmacokinetic modelling to assess the impact of antiretroviral-mediated drug-drug interactions on piperaquine antimalarial therapy during pregnancy.
    Olafuyi O; Coleman M; Badhan RKS
    Biopharm Drug Dispos; 2017 Nov; 38(8):464-478. PubMed ID: 28710808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.